Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted)

Licence status
Authorised: 06/06/2023
Active substances
Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E
Dosage Form
Powder and suspension for suspension for injection
Licence number
EU/1/23/1740/001-002
Licence holder
GlaxoSmithKline Biologicals

Product documents

Licence information

ATC code
J07BX05 respiratory syncytial virus vaccines
Legal supply status
Product subject to prescription which may not be renewed (A)
Place of sale
Supply through pharmacies only
Marketing availability
Unknown
Advertising conditions
Advertising to healthcare professionals only
Licence issued
06/06/2023